Strata Critical Medical, Inc. Q3 2026 Earnings Recap

Shares rose 3.7% after earnings, as Strata reported Q3 results ahead of its guidance and record free cash flow. Clinical services growth and earlier-than-planned logistics margin progress supported management’s outlook for 2027.

Key Takeaways

• Clinical services revenue grew more than 20% sequentially from Q2 2026, which management attributed partly to customers using Strata’s integrated transplant offering for more cases.
• Logistics revenue was near the high end of guidance despite a larger-than-expected seasonal industry decline and shorter industry trip distances.
• Strata said it reached its 2027 logistics gross margin target ahead of plan and reduced adjusted SG&A quarter over quarter.
• Free cash flow reached a record $8.6 million; the company ended the quarter with roughly $42 million in cash and short-term investments, before an anticipated $27 million in passenger-sale consideration early next year.
• Management said it expects high-teens organic adjusted EBITDA growth and 30%+ total adjusted EBITDA growth in 2027, including acquisitions; it also announced a $20 million share repurchase authorization.